echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: PI3K signaling pathway activation leads to eribulin resistance in HER2-negative breast cancer

    Br J Cancer: PI3K signaling pathway activation leads to eribulin resistance in HER2-negative breast cancer

    • Last Update: 2021-03-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Metastatic breast cancer (mBC) is an incurable disease.
    The median 5-year overall survival (OS) of patients suffering from this disease is only 25%.
    Currently, HER2 therapy and endocrine therapy are the first-choice therapies for HER2+ and HR+ tumors, respectively.
    However, for patients with ER/PR+ who are resistant to endocrine therapy or with critical symptoms of organ metastasis and TNBC (triple-negative breast cancer), chemotherapy (mainly anthracyclines and taxanes) is still the recommended therapy.

    Metastatic breast cancer (mBC) is an incurable disease.
    The median 5-year overall survival (OS) of patients suffering from this disease is only 25%.
    At present, HER2 therapy and endocrine therapy are the first-choice therapies for HER2+ and HR+ tumors, respectively.
    Metastatic breast cancer (mBC) is an incurable disease.
    The median 5-year overall survival (OS) of patients suffering from this disease is only 25%.
    At present, HER2 therapy and endocrine therapy are the first-choice therapies for HER2+ and HR+ tumors, respectively.
    Breast cancer

    Eribulin is a microtubule-targeted drug (MTA) that has been approved for the treatment of advanced or metastatic breast cancer patients with previous treatment regimens based on anthracycline and taxane drugs.
    It can significantly improve the patient's OS.

    Eribulin is a microtubule-targeted drug (MTA) that has been approved for the treatment of advanced or metastatic breast cancer patients with previous treatment regimens based on anthracycline and taxane drugs.
    It can significantly improve the patient's OS.
    Eribulin is a microtubule-targeted drug (MTA) that has been approved for the treatment of advanced or metastatic breast cancer patients with previous treatment regimens based on anthracycline and taxane drugs.
    It can significantly improve the patient's OS.

    Previous studies have shown that PIK3CA mutations are associated with adverse reactions to chemotherapy in patients with ER+/HER2-metastatic BC.
    This study aims to evaluate the role of mutations in the PI3K/AKT signaling pathway in eribulin resistance.


    Researchers evaluated the drug resistance of eribulin in the HER2-BC cell line and patient-derived xenografts, and studied its correlation with mutations in the PI3K/AKT signaling pathway.


    Inhibition of PI3K can increase the activity of eribulin

    The results showed that among 23 patients with HER2-BC transplanted tumors treated with eribulin, 11 showed disease progression.


    No correlation with ER status was detected.



    Researchers have observed that eribulin treatment can induce phosphorylation of AKT.


    Similarly, regardless of the mutation status of the PI3K/AKT signaling pathway and the status of the ER, PI3K inhibitors can reverse the generation of primary and acquired resistance of eribulin in xenograft tumor models.



    Inhibition of PI3K can reverse the resistance of eribulin treatment and restore the treatment response

    In summary, the results of the study reveal that the activation of the PI3K signaling pathway can induce the generation of primary resistance to eribulin.


    Therefore, the combination therapy of PI3K inhibitors and eribulin may become a potential treatment strategy for patients with HER2-BC.


    The activation of the PI3K signaling pathway can induce the generation of primary resistance to eribulin.



    org/10.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.